Cantor Fitzgerald analyst, Louise Chen, reiterated her Overweight rating on shares of Aridis Pharmaceuticals (NASDAQ: ARDS) on the belief that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE